Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase I/II clinical trial evaluating S65487 plus azacitidine for Acute Myeloid Leukemia; the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation [Phase 1]
Phase 1 safety study of IDH1/IDH2 inhibitors AG-120 (ivosidenib) or AG-221 (enasidenib) combined with induction and consolidation therapy fo…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating dexamethasone for relapsed or refractory acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-07Clinical Trial Update: Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia [NA]
A clinical trial evaluating integrative therapies for symptom management in adults with acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]
Phase 1 study evaluating itacitinib for prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploide…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [Phase 2]
A Phase 2 trial evaluating α/β+-T lymphocyte-depleted donor grafts from HLA-mismatched donors in multiple hematologic malignancies was termi…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: MCLA-117 in Acute Myelogenous Leukemia [Phase 1]
A Phase 1 trial of MCLA-117 for acute myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia [Phase 3]
A Phase 3 trial evaluating magrolimab added to venetoclax and azacitidine versus placebo in adults with Acute Myeloid Leukemia was terminate…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]
Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia [EARLY_Phase 1]
An early-phase trial update describing the role and mechanism of TCR-T cell therapy in Acute Myeloid Leukemia, with the study status marked …
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation [Phase 2]
Phase 2 trial evaluating olaparib for relapsed/refractory IDH-mutated acute myeloid leukemia or myelodysplastic syndrome; results posted 202…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]
Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients [Phase 2]
Phase 2 study of ponatinib (Iclusig) to prevent relapse after allogeneic stem cell transplantation in FLT3-ITD acute myeloid leukemia has co…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS [Phase 1]
Phase 1, open-label study of intravenous GSK3745417 in relapsed/refractory myeloid malignancies (AML and high-risk myelodysplastic syndrome)…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Latin American Real-world Study in Acute Leukemia
Pfizer-sponsored Latin American real-world study in acute leukemia has completed with results publicly posted.
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating intensified dosing of idarubicin for acute myeloid leukemia to assess safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]
A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study of FF-10501-01 in relapsed or refractory hematologic malignancies has completed, with results posted. The diseases studied i…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia [NA]
A clinical trial evaluating autologous hematopoietic cell transplantation for core-binding factor acute myeloid leukemia; the study status i…
-
CLINICAL_TRIALS trial_result · 2025-03-13Clinical Trial Update: BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 randomized trial evaluating pembrolizumab added to azacitidine and venetoclax as frontline therapy for unfit acute myeloid leukemia …
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating donor-derived anti-leukemia cytotoxic T lymphocytes for preventing relapse after haploidentical stem cel…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease [Phase 2]
Phase 2 trial evaluating an umbilical cord blood transplant regimen with cyclophosphamide, fludarabine, and total-body irradiation for hemat…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS [Phase 1]
A Phase 1 study evaluating CG-806 in patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes ha…